|
|
|
Volumn 25, Issue 1, 1998, Pages 65-74
|
|
Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
7 HYDROXYSTAUROSPORINE;
ALEMTUZUMAB;
ALKYLATING AGENT;
ANTHRACYCLINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
BRYOSTATIN;
CAMPTOTHECIN DERIVATIVE;
CHIMERIC ANTIBODY;
CHLORAMBUCIL;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DEPSIPEPTIDE;
DNA TOPOISOMERASE (ATP HYDROLYSING);
DOXORUBICIN;
EPIRUBICIN;
FLAVOPIRIDOL;
FLUDARABINE;
FR 901228;
GEMCITABINE;
MITOXANTRONE;
MONOCLONAL ANTIBODY;
PENTOSTATIN;
PREDNISONE;
PROTEIN P53;
PURINE DERIVATIVE;
RITUXIMAB;
THEOPHYLLINE;
UNCLASSIFIED DRUG;
VINCRISTINE;
AUTOIMMUNE HEMOLYTIC ANEMIA;
BONE MARROW SUPPRESSION;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
HUMAN;
IMMUNE DEFICIENCY;
INTRAVENOUS DRUG ADMINISTRATION;
MYALGIA;
NONHUMAN;
OPPORTUNISTIC INFECTION;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
ALKALOIDS;
ANTINEOPLASTIC AGENTS, ALKYLATING;
DNA TOPOISOMERASES, TYPE I;
FLAVONOIDS;
HUMANS;
LACTONES;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
MACROLIDES;
PIPERIDINES;
STAUROSPORINE;
|
|
EID: 0031936430
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (49)
|
|
References (94)
|
